OTCMKTS:FSNUY Fresenius SE & Co. KGaA - FSNUY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fresenius SE & Co. KGaA Please log in to your account or sign up in order to add this asset to your watchlist. $7.23 -0.04 (-0.55%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.19▼$7.4950-Day Range$6.62▼$7.7552-Week Range$4.79▼$10.99Volume32,703 shsAverage Volume31,188 shsMarket Capitalization$16.29 billionP/E Ratio8.82Dividend Yield2.23%Price Target$39.34 ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort Interest About Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) StockFresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.Read More Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter. Email Address FSNUY Stock News HeadlinesJanuary 20, 2023 | msn.comHealthcare workers union petitions FDA to recall Fresenius dialysis machinesJanuary 2, 2023 | finance.yahoo.comFresenius SE KGaA (ETR:FRE) shareholders have endured a 57% loss from investing in the stock five years agoFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.December 22, 2022 | marketwatch.comWith 3.3% CAGR, Hemodialysis & Peritoneal Dialysis Market to Witness A Pronounce Growth During 2023-2028 | 104 Pages ReportDecember 16, 2022 | finance.yahoo.comPainful week for individual investors invested in Fresenius SE & Co. KGaA (ETR:FRE) after 3.3% drop, institutions also suffered lossesDecember 6, 2022 | msn.comFMC gets new CEO after parent Fresenius flags business reviewDecember 6, 2022 | msn.comUPDATE 4-FMC boss leaves after two months as Fresenius pushes for changesDecember 5, 2022 | bloomberg.comFresenius Dialysis Unit CEO to Leave Over Strategic DifferencesFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.December 2, 2022 | finance.yahoo.comWhy Is Nevro (NVRO) Up 14.9% Since Last Earnings Report?November 29, 2022 | finance.yahoo.comIs Now An Opportune Moment To Examine Fresenius SE & Co. KGaA (ETR:FRE)?November 21, 2022 | theglobeandmail.com$FME : Fresenius Medical Care Enters Monthly Buying AreaNovember 21, 2022 | uk.finance.yahoo.comCOMMERZBANK AG (London Branch) - Pre Stabilisation - Fresenius SE EUR 3.5yr & 7yrNovember 21, 2022 | markets.businessinsider.comEQS-AFR: Fresenius SE & Co. KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statementsNovember 9, 2022 | finance.yahoo.comFresenius SE KGaA Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 8, 2022 | markets.businessinsider.comFresenius Medical Care North America Named Among 100 Healthiest WorkplacesNovember 4, 2022 | markets.businessinsider.comFresenius Medical Care North America Announces FDA Clearance of New Heat Purification System for Hemodialysis Water with Industry-Leading EfficiencyOctober 31, 2022 | seekingalpha.comFresenius SE & Co. KGaA (FSNUF) Q3 2022 Earnings Call TranscriptOctober 31, 2022 | msn.comFresenius cuts guidance again amid macroeconomic pressures and struggling North American unitOctober 31, 2022 | finance.yahoo.comFresenius Cuts 2022 Views on Worse Outlook for FMC; 3Q Earnings Fell SharplyOctober 25, 2022 | finance.yahoo.comFresenius CEO signals realignment, confirms call with Elliott - FAZ newspaperOctober 12, 2022 | seekingalpha.comFresenius cut to Hold at Jefferies citing staffing issues and inflationOctober 10, 2022 | finance.yahoo.comThe deal that showed Musk how hard it would be to exit Twitter bidOctober 8, 2022 | markets.businessinsider.comFresenius Medical Care Named to Newsweek's 100 Most Loved Workplaces for Second Consecutive YearOctober 6, 2022 | benzinga.comFresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by VizientOctober 5, 2022 | reuters.comFresenius taps pre-dialysis kidney care as drugs promise treatment changeSeptember 6, 2022 | benzinga.comFresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend® (pegfilgrastim - fpgk)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FSNUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter. Email Address FSNUY Company Calendar Last Earnings5/06/2021Today2/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:FSNUY CUSIPN/A CIKN/A Webwww.fresenius.com Phone(496) 172-6080FaxN/AEmployees316,078Year Founded1912Price Target and Rating Average Stock Price Forecast$39.34 High Stock Price Forecast$87.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+444.2%Consensus RatingModerate Buy Rating Score (0-4)2.58 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$0.82 Trailing P/E Ratio8.82 Forward P/E Ratio8.61 P/E GrowthN/ANet Income$2.15 billion Net Margins4.17% Pretax Margin8.74% Return on Equity5.58% Return on Assets2.32% Debt Debt-to-Equity Ratio0.58 Current Ratio1.32 Quick Ratio0.99 Sales & Book Value Annual Sales$44.39 billion Price / Sales0.37 Cash Flow$2.39 per share Price / Cash Flow3.03 Book Value$15.51 per share Price / Book0.47Miscellaneous Outstanding Shares2,252,950,000Free FloatN/AMarket Cap$16.29 billion OptionableNot Optionable Beta1.10 Social Links Key ExecutivesMichael SenChief Executive OfficerSara HennickenChief Financial OfficerRice PowellChief Executive Officer-Fresenius Medical CareFrancesco de MeoChief Executive Officer-Fresenius HeliosErnst WastlerChief Executive Officer-Fresenius VamedKey CompetitorsAbiomedNASDAQ:ABMDInsuletNASDAQ:PODDTeleflexNYSE:TFXPenumbraNYSE:PENBaxter InternationalNYSE:BAXView All Competitors FSNUY Stock - Frequently Asked Questions Should I buy or sell Fresenius SE & Co. KGaA stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co. KGaA in the last twelve months. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FSNUY shares. View FSNUY analyst ratings or view top-rated stocks. What is Fresenius SE & Co. KGaA's stock price forecast for 2023? 12 Wall Street analysts have issued 1-year target prices for Fresenius SE & Co. KGaA's stock. Their FSNUY share price forecasts range from $24.00 to $87.00. On average, they predict the company's stock price to reach $39.34 in the next year. This suggests a possible upside of 441.2% from the stock's current price. View analysts price targets for FSNUY or view top-rated stocks among Wall Street analysts. How have FSNUY shares performed in 2023? Fresenius SE & Co. KGaA's stock was trading at $6.99 at the beginning of 2023. Since then, FSNUY shares have increased by 4.0% and is now trading at $7.27. View the best growth stocks for 2023 here. Are investors shorting Fresenius SE & Co. KGaA? Fresenius SE & Co. KGaA saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 66,200 shares, an increase of 57.2% from the December 31st total of 42,100 shares. Based on an average trading volume of 75,800 shares, the days-to-cover ratio is presently 0.9 days. View Fresenius SE & Co. KGaA's Short Interest. How were Fresenius SE & Co. KGaA's earnings last quarter? Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) issued its earnings results on Thursday, May, 6th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. The company earned $10.83 billion during the quarter. Fresenius SE & Co. KGaA had a trailing twelve-month return on equity of 5.58% and a net margin of 4.17%. Is Fresenius SE & Co. KGaA a good dividend stock? Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) pays an annual dividend of $0.16 per share and currently has a dividend yield of 2.23%. The dividend payout ratio is 19.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, FSNUY will have a dividend payout ratio of 18.39% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for FSNUY. What is Fresenius SE & Co. KGaA's stock symbol? Fresenius SE & Co. KGaA trades on the OTCMKTS under the ticker symbol "FSNUY." How do I buy shares of Fresenius SE & Co. KGaA? Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fresenius SE & Co. KGaA's stock price today? One share of FSNUY stock can currently be purchased for approximately $7.27. How much money does Fresenius SE & Co. KGaA make? Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) has a market capitalization of $16.38 billion and generates $44.39 billion in revenue each year. The company earns $2.15 billion in net income (profit) each year or $0.82 on an earnings per share basis. How many employees does Fresenius SE & Co. KGaA have? The company employs 316,078 workers across the globe. How can I contact Fresenius SE & Co. KGaA? Fresenius SE & Co. KGaA's mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The official website for the company is www.fresenius.com. The company can be reached via phone at (496) 172-6080 or via email at ir-fre@fresenius.com. This page (OTCMKTS:FSNUY) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.